Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.
默克(US:MRK) WSJ·2026-02-23 19:00公司战略调整 - 制药公司正对其制药业务部门进行拆分 [1] - 此举旨在加强其新产品的上市推广 [1] - 战略调整的背景是为应对一项关键专利即将到期带来的挑战 [1]